Kalaris Therapeutics, Inc. (KLRS)
2.12
+0.12
(+6.00%)
USD |
NASDAQ |
Nov 03, 14:20
Kalaris Therapeutics Enterprise Value : -44.53M for Nov. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 02, 2026 | -44.53M |
| October 30, 2026 | -43.81M |
| October 29, 2026 | -41.43M |
| October 28, 2026 | -44.29M |
| October 27, 2026 | -47.86M |
| October 26, 2026 | -49.29M |
| October 23, 2026 | -47.62M |
| October 22, 2026 | -44.77M |
| October 21, 2026 | -44.05M |
| October 20, 2026 | -42.86M |
| October 19, 2026 | -46.67M |
| October 16, 2026 | -44.53M |
| October 15, 2026 | -40.00M |
| October 14, 2026 | -41.43M |
| October 13, 2026 | -39.05M |
| October 12, 2026 | -38.34M |
| October 09, 2026 | -35.96M |
| October 08, 2026 | -32.63M |
| October 07, 2026 | -31.20M |
| October 06, 2026 | -28.82M |
| October 05, 2026 | -24.77M |
| October 02, 2026 | -27.86M |
| October 01, 2026 | -24.29M |
| September 30, 2026 | -23.34M |
| September 29, 2026 | -23.10M |
| Date | Value |
|---|---|
| September 28, 2026 | -24.41M |
| September 25, 2026 | -22.63M |
| September 24, 2026 | -19.06M |
| September 23, 2026 | -17.87M |
| September 22, 2026 | -15.01M |
| September 21, 2026 | -14.89M |
| September 18, 2026 | -15.96M |
| September 17, 2026 | -16.91M |
| September 16, 2026 | -16.44M |
| September 15, 2026 | -15.96M |
| September 14, 2026 | -13.58M |
| September 11, 2026 | -11.68M |
| September 10, 2026 | -13.58M |
| September 09, 2026 | -9.535M |
| September 08, 2026 | -5.726M |
| September 04, 2026 | 0.7015M |
| September 03, 2026 | 1.654M |
| September 02, 2026 | 0.7015M |
| September 01, 2026 | 1.178M |
| August 31, 2026 | 4.034M |
| August 28, 2026 | 3.796M |
| August 27, 2026 | 5.462M |
| August 26, 2026 | 4.986M |
| August 25, 2026 | 7.843M |
| August 24, 2026 | 5.462M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Replimune Group, Inc. | 1.667B |
| Arrowhead Pharmaceuticals, Inc. | 8.182B |
| Oncolytics Biotech, Inc. | 46.19M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.192B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.52M |
| Total Expenses (Quarterly) | 11.52M |
| EPS Diluted (Quarterly) | -0.4839 |
| Earnings Yield | -95.00% |
| Normalized Earnings Yield | -95.00 |